Alpha Teknova

TKNO

Market cap $266M

HOLLISTER, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, following the close of market.

Alpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call Transcript

First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior year Company reaffirms 2026 revenue guidance of $42-44 million

HOLLISTER, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2026, on Wednesday, May 6, 2026, following the close of market.

Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript

Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue guidance of $42-44 million

HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market.

Alpha Teknova, Inc. ( TKNO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President, CEO & Director Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Presentation Operator Good day, and thank you for standing by.

Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million

HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market.